AstraZeneca PLC Technical Analysis | AstraZeneca PLC Trading: 2022-08-16 | IFCM UK
IFC Markets Online CFD Broker

AstraZeneca PLC Technical Analysis - AstraZeneca PLC Trading: 2022-08-16

AstraZeneca PLC Technical Analysis Summary

Accelerometer arrow
Strong SellSellNeutralBuyStrong Buy

Above 11035

Buy Stop

Below 10425

Stop Loss

Ara Zohrabian
Senior Analytical Expert
Articles 2451
IndicatorSignal
RSI Neutral
MACD Buy
Donchian Channel Buy
MA(200) Buy
Fractals Neutral
Parabolic SAR Buy
Fibonacci Buy

AstraZeneca PLC Chart Analysis

AstraZeneca PLC Chart Analysis

AstraZeneca PLC Technical Analysis

The technical analysis of the AstraZeneca stock price chart on daily timeframe shows #L-AZN, Daily has breached above Fibonacci 23.6 level and is rebounding above the 200-day moving average MA(200) which is rising itself. We believe the bullish momentum will continue after the price breaches above the upper boundary of Donchian channel at 11035. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed below the lower boundary of Donchian channel at 10425. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic indicator signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (10425) without reaching the order (11035), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Fundamental Analysis of Stocks - AstraZeneca PLC

AstraZeneca stock edged up after the company announced the breast cancer drug Enhertu trail results were positive. Will the AstraZeneca stock price continue rebounding?

AstraZeneca announced a late-stage trial had confirmed the benefit of breast cancer drug Enhertu. In a 600-patient trial Enhertu met the main goal of statistically significant and clinically meaningful improvement in progression-free survival. It is a measure of how long a person can live without their disease worsening. The drug also improved overall survival, a key secondary goal. Earlier AstraZeneca had secured US approval specifically targeting patients with breast cancer,, paving the way for billions in sales.

IFCM Trading Academy - New era in Forex education
Pass Your Course:
  • Get Certificate
trading academy

The best trading conditions and high-level services for our clients

We are ready to assist you on any issue 24 hours a day.

Note:
This overview has an informative and tutorial character and is published for free. All the data, included in the overview, are received from public sources, recognized as more or less reliable. Moreover, there is no guarantee that the indicated information is full and precise. Overviews are not updated. The whole information in each overview, including opinion, indicators, charts and anything else, is provided only for familiarization purposes and is not financial advice or а recommendation. The whole text and its any part, as well as the charts cannot be considered as an offer to make a deal with any asset. IFC Markets and its employees under any circumstances are not liable for any action taken by someone else during or after reading the overview.

Close support
Call to Skype Call to WhatsApp Call to telegram Call Back Call to messenger